What are the indications for Lenvatinib? What types of cancer patients does it work for?

Lenvatinib is an oral multi-target tyrosine kinase inhibitor that mainly inhibits a variety of tyrosine kinases related to tumor growth and angiogenesis, such as VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), KIT and RET, etc., play anti-tumor effects. Lenvatinib inhibits the activation of these receptors and reduces the blood supply to tumors, thereby inhibiting tumor growth and metastasis.

Indications for lenvatinib

Lenvatinib has been approved to treat many types of cancer, particularly in some patients with tumors that do not respond well to conventional treatment options. Its indications include:

1.Hepatocellular carcinoma (HCC): Lenvatinib is an effective drug for the treatment of locally progressive or metastatic hepatocellular carcinoma, especially for advanced patients who cannot undergo surgery or local treatment (such as radiofrequency ablation, liver transplantation, etc.). Lenvatinib can significantly improve the survival time of patients when treating HCC and has shown good results in clinical trials.

2.Thyroid cancer: Lenvatinib is approved for the treatment of patients with advanced dedifferentiated thyroid cancer (including differentiated thyroid cancer), especially those who are refractory to conventional treatments (such as iodine 131). Lenvatinib can significantly inhibit tumor growth and improve patients' quality of life and survival by inhibiting multi-target angiogenesis.

3.Renal cell carcinoma (RCC): Lenvatinib is also used to treat advanced renal cell carcinoma in combination with certain immunotherapy drugs (such as pembrolizumab). This combination therapy has shown enhanced efficacy in multiple clinical trials, particularly in those with advanced or metastatic renal cell carcinoma.

Lenvatinib, as a multi-target anti-tumor drug, has been approved for the treatment of a variety of cancers, especially in advanced hepatocellular carcinoma, thyroid cancer, renal cell carcinoma, endometrial cancer and other cancer types, showing significant therapeutic effects. By targeting the angiogenesis and proliferation mechanisms of tumor cells, lenvatinib provides a new treatment option for patients with advanced cancer, especially when traditional treatments are ineffective, and can significantly improve patients' survival and quality of life.

Reference materials:https://www.lenvima.com/